NÎMES, France–(BUSINESS WIRE)–Regulatory News:

Advicenne (Paris:ADVIC) (Euronext: ADVIC – FR0013296746), a
pharmaceutical company specializing in the development of adult and
pediatric therapeutic products for the treatment of orphan diseases,
today announced its intention to list its shares on the regulated market
of Euronext Brussels.

The ordinary shares of Advicenne are currently listed on the Euronext
Paris stock exchange and would also be admitted to trading on Euronext
Brussels as part of the proposed secondary listing. The company would
thus benefit from a cross listing on the two largest Euronext markets
for companies in the life sciences sector. The cross listing would have
no impact on current shareholders and Euronext Paris remains Advicenne’s
primary listing venue.

The proposed cross listing aims to further increase the visibility of
Advicenne’s shares in Belgium and beyond and fits well with the ongoing
clinical developments of Advicenne in Belgium, where the company is
conducting a Phase II/III clinical study with its lead product, ADV7103,
for the treatment of cystinuria, a rare nephrological disease.

Mr Paul Michalet, Chief Financial Officer of Advicenne, commented: “The
planned cross listing aims to give Advicenne greater visibility among
European investors, in turn supporting the liquidity of the shares.”

Dr. Luc-André Granier, Chief Executive Officer and co-founder of
Advicenne, concluded: “This project to cross-list our shares on
the Euronext Brussels and Paris markets is perfectly in line with our
international development strategy. Today, Advicenne is conducting
several clinical trials with its lead product ADV7103, including a
pivotal Phase II/III study for the treatment of cystinuria for which
Belgian Hospitals are important contributors.”

Subject to approval by Euronext and the publication of certain
documents, the Advicenne shares will be tradable on the regulated market
of Euronext Brussels as from mid-June 2019 with unchanged identification
codes (ticker: ADVIC – ISIN code: FR0013296746).

This press release does not constitute an offer to sell or the
solicitation to buy the securities mentioned and no sale of such
securities will be made in any state or jurisdiction in connection with
the proposed cross listing.

About Advicenne

Advicenne (Euronext: ADVIC) specializes in pediatric-friendly
therapeutics for the treatment of orphan diseases. The French specialty
pharmaceutical company’s lead product, ADV7103, has achieved positive
results in Europe in a pivotal Phase III study of distal Renal Tubular
Acidosis (dRTA) in children and adults, leading to its recent submission
for European marketing authorization. The commercial launch of ADV7103
in Europe is anticipated for late-2020.

In North America, ADV7103 has received clearance from the US FDA and
Health Canada for a pivotal Phase III clinical trial for the treatment
of dRTA patients. Commercial launch in the United States is anticipated
for 2021.

In addition to dRTA, ADV7103 is currently in Phase III clinical studies
for a second indication, cystinuria, an inherited renal tubulopathy.

Advicenne is listed on the Euronext Paris stock exchange (ISIN:
FR0013296746; Euronext ticker: ADVIC). Established in 2007, the company
is headquartered in Nîmes, France.

www.advicenne.com

Forward-Looking Statements

This press release contains certain forward-looking statements relating
to the business of Advicenne, which shall not be considered per se as
historical facts. Such statements include estimates for future
performance and estimates regarding anticipated operating losses, future
revenues, capital requirements and needs for additional financing. In
some cases, forward-looking statements can be identified by words such
as “could,” “should,” “may,” “expects,” “anticipates,” “believes,”
“intends,” “estimates,” “aims,” “targets” or similar words. Although the
management of Advicenne believes that these forward-looking statements
are reasonably made, they are based largely on the current expectations
of Advicenne as of the date of this press release and are subject to a
number of known and unknown risks and uncertainties and other factors
that may cause actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by these forward-looking statements.
In particular, the expectations of Advicenne could be affected by, among
other things, uncertainties involved in the placing on the market and
commercialization of Advicenne products or any other risks and
uncertainties developed or identified in any public documents filed by
Advicenne with the French Financial Markets Authority (Autorité des
marchés financiers (AMF)), including those listed in Chapter 4,
“Risk Factors,” of its reference document, filed with the latter on
December 3, 2018, under number R.18-073 and in section 8 of its
financial annual report published on April 30, 2019. Notwithstanding the
compliance with article 223-1 of the General Regulation of the AMF (the
information disclosed must be “accurate, precise and fairly presented”),
Advicenne disclaims any intention or obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.

Contacts

Advicenne
Luc-André Granier, Paul Michalet,
Julie
Rachline
E-mail: investors@advicenne.com
+33
(0)4 66 05 54 20

Financial Communications
NewCap
Emmanuel Huynh & Alexia
Faure
E-mail: advicenne@newcap.eu
+33
(0)1 44 71 94 94

Press Relations
Alize RP
Caroline Carmagnol & Tatiana
Vieira
E-mail: advicenne@alizerp.com
+33
(0)1 44 54 36 66

US Investor Relations
Rx Communications Group, LLC
Paula
Schwartz
E-mail: pschwartz@rxir.com
+001
917-322-2216